Pharmacological antagonism of glucagon signalling is an effective cardioprotective maneuverer to optimize cardiac energy production via enhancing cardiac insulin signalling and insulin-stimulated glucose oxidation post-MI. This evidence concerns the gene INS and myocardial infarction.